Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg
Condition(s):BioequivalenceLast Updated:March 26, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):BioequivalenceLast Updated:March 26, 2024Not yet recruiting
Condition(s):Breast CancerLast Updated:March 27, 2024Active, not recruiting
Condition(s):Breast CancerLast Updated:October 25, 2022Completed
Condition(s):Cancer, AdvancedLast Updated:June 21, 2018Withdrawn
Condition(s):Breast CancerLast Updated:February 28, 2020Unknown status
Condition(s):Breast CancerLast Updated:August 30, 2023Recruiting
Condition(s):Advanced Breast Cancer FemaleLast Updated:January 20, 2022Completed
Condition(s):Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast CancerLast Updated:December 22, 2023Recruiting
Condition(s):Metastatic Breast Cancer; Advanced Breast Cancer; Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of BreastLast Updated:March 31, 2023Completed
Condition(s):Breast CancerLast Updated:March 13, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.